Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 692 | 28,866 | 21,794 | 30,128 |
| Operating expenses: | ||||
| Cost of sales | 39 | 33 | 147 | 63 |
| Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively | 17,443 | 15,747 | 30,199 | 31,050 |
| Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively | 9,750 | 9,350 | 18,984 | 20,958 |
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 |
| (Loss) income from operations | (26,540) | 3,736 | (27,536) | (21,943) |
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's R&D?
- Lexicon Pharmaceuticals (LXRX) reported R&D of $17.44M in Q2 2026.
- How has Lexicon Pharmaceuticals's R&D changed year-over-year?
- Lexicon Pharmaceuticals's R&D increased by 10.8% year-over-year, from $15.75M to $17.44M.
- What is the long-term trend for Lexicon Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's R&D has grown at a 2.7% compound annual growth rate (CAGR), from $55.05M to $61.12M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Lexicon Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude